82 related articles for article (PubMed ID: 38072962)
1. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Federico C; Alhallak K; Sun J; Duncan K; Azab F; Sudlow GP; de la Puente P; Muz B; Kapoor V; Zhang L; Yuan F; Markovic M; Kotsybar J; Wasden K; Guenthner N; Gurley S; King J; Kohnen D; Salama NN; Thotala D; Hallahan DE; Vij R; DiPersio JF; Achilefu S; Azab AK
Nat Commun; 2020 Nov; 11(1):6037. PubMed ID: 33247158
[TBL] [Abstract][Full Text] [Related]
2. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.
Xing L; Lin L; Yu T; Li Y; Cho SF; Liu J; Wen K; Hsieh PA; Kinneer K; Munshi N; Anderson KC; Tai YT
Leukemia; 2020 Aug; 34(8):2150-2162. PubMed ID: 32060401
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.
Marino S; Petrusca DN; Bishop RT; Anderson JL; Sabol HM; Ashby C; Layer JH; Cesarano A; Davé UP; Perna F; Delgado-Calle J; Chirgwin JM; Roodman GD
Haematologica; 2024 May; 109(5):1501-1513. PubMed ID: 37981834
[TBL] [Abstract][Full Text] [Related]
4. NCX1/Ca
Li T; Xiao P; Qiu D; Yang A; Chen Q; Lin J; Liu Y; Chen J; Zeng Z
Cell Commun Signal; 2024 May; 22(1):258. PubMed ID: 38711131
[TBL] [Abstract][Full Text] [Related]
5. A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.
Gao J; Zhou J; Zhang M; Zhang Y; Zeng Y; Li S; Xu K; Yao R
Mol Cell Biochem; 2024 Apr; 479(4):843-857. PubMed ID: 37204666
[TBL] [Abstract][Full Text] [Related]
6. Lactate Decreases Bortezomib Sensitivity and Predicts Poor Clinical Outcomes of Multiple Myeloma.
Ma NY; Li Q; Li XL; Zeng YJ; Huang DZ; Duan YS; Xia J; Liu BD; Rao LY; Rao J; Zhang X
Curr Med Sci; 2023 Aug; 43(4):679-688. PubMed ID: 37326888
[TBL] [Abstract][Full Text] [Related]
7. Identification of
Zhang N; Lan R; Chen Y; Hu J
Open Life Sci; 2024; 19(1):20220848. PubMed ID: 38623585
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species-mediated inhibition of nuclear factor kappa-B signal and stemness properties.
Shao R; Liu S; Liu W; Song C; Liu L; Zhu L; Peng F; Lu Y; Tang H
MedComm (2020); 2024 May; 5(5):e562. PubMed ID: 38737470
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans.
Prabhu KS; Ahmad F; Kuttikrishnan S; Leo R; Ali TA; Izadi M; Mateo JM; Alam M; Ahmad A; Al-Shabeeb Akil AS; Bhat AA; Buddenkotte J; Pourkarimi E; Steinhoff M; Uddin S
Cell Death Discov; 2024 May; 10(1):225. PubMed ID: 38724504
[TBL] [Abstract][Full Text] [Related]
10. Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.
Ding JH; Yuan LY; Chen GA
Oncol Lett; 2017 Feb; 13(2):647-654. PubMed ID: 28356941
[TBL] [Abstract][Full Text] [Related]
11. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy.
Yang M; Chen Y; Zhu L; You L; Tong H; Meng H; Sheng J; Jin J
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254683
[TBL] [Abstract][Full Text] [Related]
12. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.
Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L
J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782
[TBL] [Abstract][Full Text] [Related]
13. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
14. [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].
Wang YR; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1584-1587. PubMed ID: 37846721
[TBL] [Abstract][Full Text] [Related]
15. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
16. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
Dutta D; Liu J; Wen K; Kurata K; Fulciniti M; Gulla A; Hideshima T; Anderson KC
Blood Cancer J; 2023 Dec; 13(1):184. PubMed ID: 38072962
[TBL] [Abstract][Full Text] [Related]
17. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF.
He C; Zhang M; Liu L; Han Y; Xu Z; Xiong Y; Yan F; Su D; Chen H; Zheng Y; Cheng F
Acta Biomater; 2022 Apr; 143():406-417. PubMed ID: 35218967
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]